P1154: STUDY ZILO‐301: A PHASE 3, RANDOMIZED, DOUBLE‐BLIND, PLACEBO‐CONTROLLED, MULTICENTER STUDY OF ZILOVERTAMAB PLUS IBRUTINIB VS IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA.

Autor: Yazji, S., Hamburger, S., Wang, Y., Yavrom, S., Pietrofeso, A., Bliss, R., Breitmeyer, J. B., Dreyling, M., Wang, M.
Zdroj: HemaSphere; 2022 Supplement 3, Vol. 6, p1041-1042, 2p
Databáze: Complementary Index
Externí odkaz: